Clinical Trials Logo

Clinical Trial Summary

Intravenous administration of esketamine is an effective recognized therapeutic option in refractory pain in CRPS, which sometimes in at least a part of the patients has a prolonged therapeutic effect. Unfortunately, CRPS literature contains a wide range of ketamine dosing regimens with the result that clinical protocols on dosage and administration are very heterogeneous. The current esketamine regimen in Erasmus MC consists of a 6-day hospital admission for continuous administration. In the Netherlands, both inpatient and outpatient esketamine treatments are offered. Inpatient and outpatient ketamine treatments have never been compared in randomized controlled trials and it is therefore unknown whether these two dosing regimens are equally effective. The primary objective is to demonstrate non-inferiority of experimental esketamine administration of 6x 1 day per 2 weeks (in total 3 months) as compared with standard esketamine administration of 1x 6 consecutive days. The end of study is at 6 months after the start of the study/treatment.


Clinical Trial Description

Rationale: Complex regional pain syndrome (CRPS) is a debilitating chronic pain condition of one or more limbs. Its diagnosis is based on (combinations of) underlying pathophysiological mechanisms. Achieving relevant pain relief fails in a significant proportion of CRPS patients. Intravenous administration of esketamine is an effective therapeutic option in refractory pain in CRPS, which in at least a part of the patients has a prolonged therapeutic effect. Unfortunately, CRPS literature contains a wide range of ketamine dosing regimens with the result that clinical protocols on dosage and administration are very heterogeneous. In the Netherlands, both inpatient and outpatient esketamine treatments are offered. The current esketamine regimen in Erasmus MC consists of a 6-day hospital admission for continuous administration; however, logistical boundaries limit this therapy. Esketamine infusions in an outpatient setting might increase flexibility and availability of esketamine treatment. However, inpatient and outpatient ketamine treatments have never been compared in randomized controlled trials and it is therefore unknown whether these two dosing regimens are equally effective. Objective: The primary objective is to demonstrate non-inferiority of experimental esketamine administration of 6x 1 day per 2 weeks (in total 3 months) as compared with standard esketamine administration of 1x 6 consecutive days at 3 months after the start of the study/treatment. The secondary objective is to assess pain scores till 6 months follow-up, logistical problems, adverse effects, questionnaires, thermography and quantitative sensory testing in both treatment groups. Study design: Prospective, randomized, non-inferiority study in 60 patients Study population: Sixty adult patients with chronic pain due to CRPS Intervention: All patients will receive intravenous esketamine. The standard treatment group receives intravenous esketamine for 6 consecutive days (in hospital). The experimental intervention group visits the outpatient clinic to receive intravenous esketamine in day-care setting every 2 weeks for 3 months. Main study parameters/endpoints: The main study parameter is pain intensity, measured by means of Numerical Rating Scale (NRS), to demonstrate non-inferiority of the experimental treatment after three months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05212571
Study type Interventional
Source Erasmus Medical Center
Contact Thomas JP Mangnus, MD
Phone +31610746907
Email [email protected]
Status Recruiting
Phase N/A
Start date April 19, 2022
Completion date February 1, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04066933 - Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M
Enrolling by invitation NCT04597866 - Treatment of Complex Regional Pain Syndrome, a Long-term Follow-up
Completed NCT04060875 - Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain
Terminated NCT01954888 - Impact of the Ultrasound-guided Approach on the Efficiency and Safety of the Stellate Ganglion Block in Chronic Pain N/A
Terminated NCT00689585 - Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS) Phase 2
Recruiting NCT00377468 - Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study) Phase 2
Recruiting NCT04732325 - Sensory Testing of Multiple Forms of Spinal Cord Stimulation for Pain N/A
Completed NCT03174249 - Exposure Therapy Combined With Cortical Interventions for CRPS-II N/A
Recruiting NCT04144972 - Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain N/A
Completed NCT02490436 - Novel Treatment Option for Neuropathic Pain Phase 2
Withdrawn NCT03316066 - Comparison of Volumes of Local Anesthetics on the Efficiency and Safety of Stellate Ganglion Block for CRPS of the Arm N/A
Completed NCT03291197 - Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome Phase 4
Recruiting NCT05034835 - Impact of Compression Garments on Pain in Patients With Complex Regional Pain Syndrome of the Upper Limbs. N/A
Recruiting NCT02957240 - Graded Motor Imagery for Women at Risk for Developing Type I CRPS Following Closed Treatment of Distal Radius Fractures N/A
Terminated NCT00891397 - Pregabalin Versus Placebo as an Add on for Complex Regional Pain Syndrome (CPRS) of the Upper Limb Managed by Stellate Ganglion Block (The PREGA Study) N/A
Recruiting NCT05160038 - Embodied Virtual Reality for Chronic Pain N/A
Active, not recruiting NCT03887962 - Virtual Environment Rehabilitation for Patients With Motor Neglect Trial N/A
Recruiting NCT05337501 - Prognostic Factors for Complex Regional Pain Syndrome N/A
Completed NCT04849897 - Virtual Reality Guided Imagery for Chronic Pain N/A
Not yet recruiting NCT04744675 - Peripheral Nerve Injections for CRPS Phase 4